



RECEIVED

JUL 18 2001

1646
#4

TECH CENTER 1600/2900 PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J. Henkin, et al.

Group Art No.: 1646

Serial NO.: 09/832,733

Examiner: (not yet assigned)

Filed: April 11, 2001

Title: PEPTIDE ANTIANGIOGENIC
DRUGS

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Case No.: 6356.US.03

Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: July 13, 2001

Tanya Benavidez 7/13/01
Tanya Benavidez Date

Assistant Commissioner for Patents
Washington D.C. 20231

Dear Sir:

TRANSMITTAL LETTER

Enclosed herewith for the patent application identified above entitled PEPTIDE ANTIANGIOGENIC DRUGS are the following:


1. Communication;
2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and
3. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully Submitted,
J. Henkin, et al.

ABBOTT LABORATORIES
D-0377/AP6D-2
100 Abbott Park Road
Abbott Park IL 60064-6050
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Gregory W. Steele
Gregory W. Steele
Registration No. 33,796
Attorney for Applicants



RECEIVED

JUL 18 2001
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicants: J. Henkin, et al.

Group Art No.: 1646

Serial NO.: 09/832,733

Examiner: (not yet assigned)

Filed: April 11, 2001

Title: PEPTIDE ANTIANGIOGENIC
DRUGS

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Case No.: 6356.US.03

Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: July 13, 2001

Tanya Benavidez 7/13/01
Tanya Benavidez Date

Assistant Commissioner for Patents
Washington D.C. 20231

Dear Sir:

COMMUNICATION

Applicants received a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated June 26, 2001.

Applicants note that all of the peptides disclosed and claimed in the present application require the presence of at least one D-amino acid. See, e.g., page 3, line 13; Examples 1-26; and Claim 1, line 37. The presence of a D-amino acid in the peptide sequence removes the application from the requirements of 37 C.F.R. 1.821-1.825.

Withdrawal of the Notice to comply is respectfully requested.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully Submitted,
J. Henkin, et al.

ABBOTT LABORATORIES
D-0377/AP6D-2
100 Abbott Park Road
Abbott Park IL 60064-6050
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Gregory W. Steele
Gregory W. Steele
Registration No. 33,796
Attorney for Applicants

**RECEIVED**

Page 1 of 2

JUL 18 2001

UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900
COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/832,733	04/11/2001	Jack Henkin	6356.US.03

CONFIRMATION NO. 3455

FORMALITIES LETTER



Steven F. Weinstock
Abbott Laboratories
Dept. 377 Bldg. AP6D-2
100 Abbott Park Road
Abbott Park, IL 60064-6050

Date Mailed: 06/26/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

nb

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE